New developments in the management of cytomegalovirus infection and disease after renal transplantation.
The clinical management of cytomegalovirus infection and disease in renal transplant recipients has recently been significantly improved with the availability of data on prophylaxis with oral ganciclovir and valacyclovir. In addition, significant progress in early diagnosis and the quantitation of viral load has been achieved. The influence of novel immunosuppressants on the clinical course of cytomegalovirus infection has been clarified to some extent by recent clinical data. The identification of risk factors for cytomegalovirus disease beyond seroconstellation and immunosuppression is an ongoing process that might lead to a more targeted use of antiviral agents, given the risk of ganciclovir resistance. The understanding of the effects of cytomegalovirus on long-term graft outcome still needs to be deepened in order to design cytomegalovirus-specific interventions to improve graft survival.
Department of Medicine, Division of Nephrology and Dialysis, University of Vienna, Austria. josef.kletzmayr@nephro.imed3.akh-wien.ac.at
J
J
Kletzmayr
E
E
Kreuzwieser
R
R
Klauser
D003586:Cytomegalovirus Infections / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*